Abivax Emerges as Prime Takeover Target in Booming IBD Market

The market for inflammatory bowel diseases (IBD) is one of the most dynamic segments of the entire biopharmaceutical industry. The therapeutic area of ​​ulcerative colitis alone is valued at around US$20 billion globally, and this figure is rising: despite numerous biologics and Janus kinase inhibitors, a significant proportion of patients are considered inadequately treated.

This very gap in care makes the sector strategically highly attractive to large pharmaceutical companies. Pfizer acquired Arena Pharmaceuticals for US$6.7 billion in 2022, and Merck acquired Prometheus Biosciences for US$10.8 billion in 2023. Both companies thus secured access to differentiated mechanisms of action in gastroenterology. The willingness to pay substantial premiums for promising candidates has been pronounced in the IBD field for years.

Rising IBD demand and breakthrough therapies drive takeover interest in Abivax

In this environment, the French biotech company Abivax, with its drug Obefazimod, has positioned itself as one of the most promising takeover targets. Obefazimod works via a novel mechanism: As a so-called miR-124 enhancer, it interferes with the body’s own immune regulation without having a classic immunosuppressive effect—a crucial advantage over established therapies. In July 2025, Abivax delivered clinical proof. for this IBD drug.

The Phase III induction data showed highly significant remission rates of 20.8 percent compared to 4.4 percent with placebo IBD drugs. The share price subsequently increased by around 470 percent, one of the most spectacular price jumps in the European biotech sector in years. Since then, takeover rumors have intensified. In December of last year, Reuters reported that Eli Lilly was considering an acquisition worth around 15 billion euros. Although the Abivax CEO dismissed the speculation as “noise”, the signals from the market remain clear.

Significant surcharges paid

The premiums paid in comparable transactions fuel takeover speculation. In recent IBD acquisitions, the premiums over the unaffected share price ranged from 50 to 80 percent, with valuations reaching four to six times the estimated peak sales.

Based on peak sales estimates of around €3.5 billion for obefazimod in the ulcerative colitis indication alone, this suggests considerable upside potential for the French company’s valuation.

Conclusion

In the event of a takeover, a price of around €160 per Abivax share would be quite realistic. However, even without such a deal, the stock has upside potential.

The Phase III maintenance data, expected at the end of the second quarter of 2026, should provide the next catalyst. If the results for the new IBD treatment are positive, approval will be within reach, along with a revaluation of the company.

__

(Featured image by Sasun Bughdaryan via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in boerse-online. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.